• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Sanofi, Novo, Lilly Shape up for Big Insulin Fight

Article

Competition is ramping up in the multibillion-dollar market for long-lasting insulins, with Novo Nordisk and Eli Lilly lining up new products that could trump Sanofi's top-seller Lantus.

Worldwide, Lantus has some 80 percent of the market for long-acting, or basal, insulins used to treat diabetes and the product had sales of around $5 billion last year. Now rivals are closing in.

Read the full story:

http://hcp.lv/KahW6a

Source: Reuters

Related Videos
Dr Guru Sonpavde
Bevey Miner, executive vice president of health care strategy and policy, Consensus Cloud Solutions
Chase D. Hendrickson, MD, MPH
dr kimberly maxfield
Amal Trivedi, MD
Takiyah Durham, MBA, and Margaret Larkins-Pettigrew, MD
Related Content
© 2023 MJH Life Sciences
AJMC®
All rights reserved.